Tuesday, October 13 2026

Pakistan, Ethiopia move to fast-track drug registration for exports
Federal Minister for Commerce Jam Kamal Khan called for expediting regulatory approvals for Pakistani pharmaceutical companies seeking access to the Ethiopian market, as Pakistan and Ethiopia discussed expanding bilateral trade, investment and economic cooperation. The discussions took place during a meeting with Ethiopian Ambassador to Pakistan Dr Oumer Hussein Oba, who called on the minister at his office in Islamabad. Coordinator to the Prime Minister on Commerce and Industries Rana Ihsaan Afzal, Federal Secretary for Commerce Jawad Paul and senior Ministry officials attended the meeting, read a statement on Tuesday.
Related news categories: business economic-indicators misc pharma

Monday, October 12 2026

Pakistani diabetes medicines match multinational brands: experts
In Pakistan, where millions of families struggle to make both ends meet and cannot afford costly treatment, a local study found that Pakistani biosimilar medicines deliver diabetes control and weight loss comparable to their multinational counterparts. The findings were presented at the concluding day of PESCON 2026, the Pakistan Endocrine Society’s 24th annual conference. Medical experts said Pakistani alternatives cost about one quarter of multinational brands, potentially making treatment accessible to poorer patients.
Related news categories: business economic-indicators misc pharma

Wednesday, October 07 2026

Pharma listed cos: FY26 profits surge 28pc to Rs42.2bn YoY
Profitability of Pakistan’s listed pharmaceutical sector increased 28 percent year-on-year (YoY) to Rs42.2 billion in FY26, mainly supported by price-led growth and lower finance costs, according to a Research report issued. However, sector earnings declined 2 percent YoY and 26 percent quarter-on-quarter (QoQ) in 4QFY26, primarily due to the loss posted by The Searle Company Limited (SEARL) during the quarter. Excluding SEARL, sector profitability increased 6 percent YoY but declined 4 percent QoQ to Rs9.3 billion in 4QFY26.
Related news categories: business economic-indicators pharma psx stock-exchanges

Wednesday, September 23 2026

MACTER FY26 profit softens 14%
Macter International Limited (PSX: MACTER) reported a 14% drop in its consolidated net profit for the fiscal year ended June 30, 2026, recording Rs675.17m compared to Rs786.93m in the preceding year. Reflecting this bottom-line compression, basic and diluted earnings per share (EPS) for the year stood at Rs14.83, down from Rs16.95 in FY25. The primary factor weighing on final earnings was higher taxation outlays and selling expense inflation, which offset a strong 17% expansion in top-line revenue. Consolidated revenue from contracts with customers grew by 17% year-on-year to Rs12.17bn, up from Rs10.36bn in FY25. Cost of sales expanded by 11% to Rs6.25bn, allowing gross profit to increase 25% to Rs5.92bn compared to Rs4.73bn in the prior year.
Related news categories: business economic-indicators misc pharma